Cost Effectiveness of Dapagliflozin Added to Standard of Care for the Management of Diabetic Nephropathy in the USA
Tadesse Melaku Abegaz, Vakaramoko Diaby, Fatimah Sherbeny, Askal Ayalew Ali
Topics & Concepts
DapagliflozinMedicineCost effectivenessQuality-adjusted life yearIncremental cost-effectiveness ratioAdverse effectIntensive care medicineDiabetes mellitusInternal medicineRisk analysis (engineering)Type 2 diabetesEndocrinologyDiabetes Treatment and ManagementChronic Kidney Disease and DiabetesHyperglycemia and glycemic control in critically ill and hospitalized patients